Immunovia (IMMNOV.ST) Stock Analysis & AI Equity Report
Immunovia (IMMNOV.ST) overview
Immunovia (IMMNOV.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Immunovia reported revenue of SEK 0.7m and operating profit of SEK -79.5m; the year-end share price was 0.23 SEK and market capitalisation was SEK 78.2m. Immunovia is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Immunovia's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-06. Data will be refreshed during report generation.
About Immunovia
Immunovia AB (publ) develops and commercializes blood-based diagnostics for early detection of pancreatic cancer, primarily for people at elevated genetic or family risk. Its main product is PancreaSure, a test based on protein and biomarker analysis, and the company also provides clinical, laboratory, and commercialization capabilities as it focuses on the U.S. market.
Generate the Immunovia report
Immunovia is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Immunovia and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.